23000-14-8

Basic information

• Product Name: 2,5-DIMETHYL-1,3-OXAZOLE-4-CARBOXYLIC ACID
• Synonyms: 2,5-DIMETHYL-1,3-OXAZOLE-4-CARBOXYLIC ACID;2,5-Dimethyl-1,3-oxazole-4-carboxylic acid 97%;2,5-Dimethyloxazole-4-carboxylic acid;4-Oxazolecarboxylic acid, 2,5-diMethyl-;4-Carboxy-2,5-dimethyl-1,3-oxazole;2,5-Dimethyl-1,3-oxazole-4-carboxylicacid97%
• CAS NO: 23000-14-8
• Molecular Formula: C₆H₇NO₃
• Molecular Weight: 141.12
• Mol File: 23000-14-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 232 °C
• Boiling Point: 267.4oCat760mmHg
• Flash Point: 115.5oC
• Appearance: /
• Density: 1.276g/cm³
• Vapor Pressure: 0.00406mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: 2-8°C
• PKA: 4.01±0.10(Predicted)
• CAS DataBase Reference: 2,5-DIMETHYL-1,3-OXAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYL-1,3-OXAZOLE-4-CARBOXYLIC ACID(23000-14-8)
• EPA Substance Registry System: 2,5-DIMETHYL-1,3-OXAZOLE-4-CARBOXYLIC ACID(23000-14-8)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• HazardClass: IRRITANT
• Hazardous Substances Data: 23000-14-8(Hazardous Substances Data)

Usage

General Description

2,5-Dimethyl-1,3-oxazole-4-carboxylic acid is an organic compound with a complex molecular structure. It is classified as an oxazole, which refers to a family of organic compounds containing a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom. As the name suggests, this compound is composed of a 2,5-dimethyl-1,3-oxazole ring attached to a carboxylic acid group. This chemical is used in the field of organic synthesis where it serves as a precursor or intermediate in the formation of more complex molecules. It is predominantly used in laboratory settings and is not typically encountered outside of specialized fields.

InChI:InChI=1/C6H7NO3/c1-3-5(6(8)9)7-4(2)10-3/h1-2H3,(H,8,9)

Upstream product

• 23000-15-9 2,5-Dimethyl-4-oxazolcarbonsaeure-ethylester 
• 82123-42-0 2,5-dimethyloxazole-4-carbonitrile 
• 1198279-66-1 benzyl 2,5-dimethyloxazole-4-carboxylate 
• 124576-56-3 benzyl 2-acetamido-3-oxobutanoate 
• 60379-78-4 2-acetylamino-3-bromo-but-2-enoic acid tert-butyl ester 
• 5431-93-6 ethyl 2-(acetylamino)-3-oxobutanoate 
• 23012-17-1 2-methyl-1,3-oxazol-4-carboxylic acid 
• 116097-66-6 ethyl 4-cyano-5-methyloxazol-2-ylacetate 
• 116097-67-7 4-cyano-5-methyloxazol-2-ylacetic acid 
• 174902-36-4 ethyl 2-acetyl-4-methyl-5-oxo-2,5-dihydroisoxazole-3-carboxylate 
• 74-88-4 methyl iodide 
• 63888-23-3 tert-butyl 2,5-dimethyloxazole-4-carboxylate 

Downstream Products

• 113366-77-1 2-ethyl-5-methyloxazole-4-carboxylic acid 
• 113366-75-9 5-ethyl-2-methyloxazole-4-carboxylic acid 
• 92901-94-5 (2,5-dimethyl-1,3-oxazol-4-yl)methanol 
• 92901-90-1 (2,5-Dimethyl-4-oxazolyl)<1-(ethoxymethyl)-2(phenylthio)-1H-imidazol-5-yl>methanone 
• 92901-89-8 α-<1-(Ethoxymethyl)-2-(phenylthio)-1H-imidazol-5-yl>-2,5-dimethyl-4-oxazolemethanol 
• 1246830-61-4 (S)-2-{[(3S,8S)-3-[3-(3,4-dichloro-benzyloxy)-phenyl]-7-(2,5-dimethyl-oxazole-4-carbonyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino}-3-[4-(2,3-dimethyl-pyridin-4-yloxy)-phenyl]-propionic acid methyl ester 
• 1246830-58-9 (S)-2-{[(3S,8S)-3-(3-cyclopentylmethoxy-phenyl)-7-(2,5-dimethyl-oxazole-4-carbonyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino}-3-[4-(2,3-dimethyl-pyridin-4-yl)-phenyl]-propionic acid methyl ester 
• 1246830-55-6 (S)-2-{[(3S,8S)-3-(3-cyclohexylmethoxy-phenyl)-7-(2,5-dimethyl-oxazole-4-carbonyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino}-3-[4-(2,3-dimethyl-pyridin-4-yl)-phenyl]-propionic acid methyl ester 
• 1246830-52-3 C₄₈H₄₄Cl₂N₄O₈ 

Relevant articles and documents

POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS

The disclosure provides compounds of the formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables A, R1, and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering to a patient infected with the bacteria, simultaneously or sequentially, a therapeutically effective amount of the antibacterial agent and a compound of formula (I).

Total synthesis of siphonazole and its O-methyl derivative, structurally unusual bis-oxazole natural products

The details of the first syntheses of the unusual bis-oxazole natural products siphonazole and its O-methyl derivative are reported. The cinnamyl substituted oxazole was constructed using diazocarbonyl chemistry, whereby the cinnamamide was reacted with the rhodium carbene derived from methyl 2-diazo-3-oxobutanoate to give a β-ketoamide that was cyclodehydrated to the corresponding oxazole-4-ester. Reduction to the corresponding aldehyde was followed by coupling with a zinc reagent derived from methyl 2-iodomethyl-5-methyloxazole-4-carboxylate, also prepared using rhodium carbene chemistry, to give, after oxidation of the resulting secondary alcohol, the desired bis-oxazole ketone. The syntheses were completed by hydrolysis of the ester and coupling of the 2,4-pentadienylamine side chain. The 2008 Royal Society of Chemistry.

Isoxazole-Oxazole Conversion by Beckmann Rearrangement

A novel base-catalysed isoxazole-oxazole ring transformation was realized in the conversion of ethyl 5-hydroxy-3-(5-methylisoxazol-4-yl)isoxazole-4-carboxylate into 4-cyano-5-methyloxazol-2-ylacetic acid.A new process was developed for the preparation of t-4-amino-c-2-methyl-6-oxotetrahydropyran-r-3-carboxylic acid hydrochloride, a starting material for the synthesis of thienamycin.